Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.41 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.41 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.41 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.38 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.36 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.36 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212822 | 0.98 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Bromide SCHEMBL20984918 | 0.96 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Sulfuric Acid SCHEMBL20984339 | 0.87 | CA2 (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Oxalic Acid SCHEMBL20984309 | 0.87 | FADS1 (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Phosphoric Acid SCHEMBL20984415 | 0.87 | FADS1 (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Nitric Acid SCHEMBL20984573 | 0.84 | CA2 (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4704985 | 0.81 | LMNA (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16740946 | 0.80 | KIF11 (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL23641249 | 0.79 | HDAC4 (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1426164 | 0.78 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | claimed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | claimed |
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| CN-113329996-B | Compounds and methods for treating hedgehog pathway related disorders | 博远医药(苏州)有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-109535060-B | Hedgehog pathway inhibitor and preparation method and application thereof | 苏州麦迪耐斯医药科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-113329996-A | Compounds and methods for treating hedgehog pathway related disorders | 苏州麦迪耐斯医药科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | disclosed |
| EP-3810573-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | Suzhou Mednes Pharma Tech Co., Ltd. (CN) | 2021-04-28 | — | — | EP | disclosed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | disclosed |
| CN-107663161-A | A kind of continuous stream synthesis technique of phenylhydrazine salt and substituted benzene hydrazonium salt | 上海惠和化德生物科技有限公司 | 2018-02-06 | — | — | CN | disclosed |
| US-9255094-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| CN-102480955-B | Pyrido [4,3-b ] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-05 | — | — | CN | disclosed |
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2424364-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127177-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GRIN2D 36/4885GRIN3B 32/4885GRIN1 86/4885 |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | GRIN2D 4542/4885GRIN3B 3577/4885GRIN1 4141/4885 |
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | GRIN2D 4557/4885GRIN3B 3601/4885GRIN1 4271/4885 |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GRIN2D 36/4885GRIN3B 32/4885GRIN1 86/4885 |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | HPD, TYR, PDK2 | GRIN2D 3444/4885GRIN3B 4754/4885GRIN1 4283/4885 |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | HPD, TYR, PDK2 | GRIN2D 3444/4885GRIN3B 4754/4885GRIN1 4283/4885 |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | GRIN2D 4542/4885GRIN3B 3577/4885GRIN1 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.